Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Bicara Therapeutics Inc. (NASDAQ: BCAX), a clinical-stage biopharmaceutical company developing the bifunctional antibody ficerafusp alfa for solid tumors. As a public issuer, Bicara submits periodic and current reports that provide detail on its financial position, research and development spending, and key clinical and corporate events.
Among the filings available for review are Form 10-K annual reports and Form 10-Q quarterly reports, which describe operating expenses, including research and development and general and administrative costs, as well as cash, cash equivalents, and investments. These documents give insight into how Bicara funds the pivotal FORTIFI-HN01 trial in recurrent/metastatic head and neck squamous cell carcinoma and its Phase 1/1b expansion cohorts in head and neck cancer and metastatic colorectal cancer.
Form 8-K current reports, such as those referenced in the provided data, furnish press releases on quarterly financial results and business updates. These filings often summarize recent clinical milestones for ficerafusp alfa, including dose-optimization progress, expansion cohort data, and regulatory developments like Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
Investors can also use this page to access exhibits attached to Bicara’s SEC filings, which may include detailed financial statements, risk factor discussions, and other disclosures relevant to evaluating a clinical-stage biotechnology company. Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy reports, helping readers quickly identify information on operating expenses, cash runway, clinical trial status, and other factors that influence the outlook for BCAX.
Bicara Therapeutics Inc. provides its annual business update focused on ficerafusp alfa, a bifunctional EGFR/TGF-β antibody for solid tumors. The company is running the global double-blind FORTIFI-HN01 Phase 2/3 pivotal trial in first-line HPV-negative head and neck squamous cell carcinoma, targeting substantial enrollment by the end of 2026 and an interim analysis in mid-2027.
Earlier Phase 1/1b data in 1L recurrent/metastatic HPV-negative head and neck cancer showed a confirmed overall response rate of 54% at the 1500mg weekly dose in combination with pembrolizumab, with a median overall survival of 21.3 months. Bicara is also exploring ficerafusp alfa in additional tumors, including colorectal, cutaneous squamous cell, and anal squamous cell carcinomas, and reports a generally manageable safety profile dominated by EGFR-related rash and low-grade mucosal bleeding events.
Bicara Therapeutics reported fourth quarter and full year 2025 results and outlined progress on its lead oncology program ficerafusp alfa. For 2025, net loss was $137.95 million, up from $67.99 million in 2024, driven mainly by higher research and development spending.
Cash, cash equivalents and marketable securities totaled $414.8 million as of December 31, 2025, plus $161.8 million in net proceeds from an oversubscribed public offering in early 2026, and the company expects this to fund operations into the first half of 2029. Bicara initiated Phase 3 of its pivotal FORTIFI-HN01 trial in HPV‑negative head and neck cancer, selected a 1500 mg weekly dose of ficerafusp alfa, and is developing a less frequent loading and every‑three‑week maintenance regimen. Management highlighted plans for substantial FORTIFI‑HN01 enrollment by the end of 2026 and an interim analysis in mid‑2027.
Bicara Therapeutics Chief Medical Officer David Raben reported an option exercise and related share sale. He exercised stock options to acquire 5,500 shares of common stock at an exercise price of $3.7898 per share, then sold 5,500 shares at a weighted average price of $18.9508 per share.
The filing states that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. Following these transactions, Raben directly holds 55,286 shares of Bicara Therapeutics common stock.
BCAX reports an issuer-related planned sale of 5,500 common shares tied to an exercise of stock options to be effected on 03/25/2026 for cash. The filing also discloses recent open-market sales by David Raben: 200 shares on 03/03/2026 for $3,690.00 and 16,300 shares on 03/04/2026 for $301,920.01.
Bicara Therapeutics Inc. Chief Financial Officer Hyep Ivan exercised stock options and sold shares in a pre-planned transaction. On March 23, 2026, he exercised options for 9,200 shares of common stock at an exercise price of $3.7898 per share, then sold the same 9,200 shares at a weighted average price of $18.5161 per share in multiple trades between $18.15 and $18.84. The sale was carried out under a Rule 10b5-1 trading plan adopted on February 13, 2025, indicating the trades were pre-scheduled rather than opportunistic. Following these transactions, Ivan directly owned 145,355 shares of Bicara Therapeutics common stock. The exercised options were part of a grant vesting in sixteen equal quarterly installments after April 5, 2023 and are scheduled to expire on April 5, 2033.
BCAX insider reported proposed sale of 9,200 common shares by exercise of stock options, listed as to be sold on 03/23/2026 for cash. The filing also lists three reported dispositions in the prior three months: 01/22/2026 1,882 shares, 03/03/2026 13,555 shares, and 03/04/2026 2,963 shares.
Bicara Therapeutics Inc. director and Chief Executive Officer Claire Mazumdar exercised stock options and sold the related shares over three days. She exercised options for a total of 15,000 shares of Common Stock at an exercise price of $3.7898 per share, then sold 15,000 shares in open-market transactions at weighted-average prices between $18.73 and $19.26, as disclosed in the price ranges. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. Following the transactions, she holds 339,392 shares of Common Stock directly.
BCAX affiliate reported planned sale of Common Stock and multiple recent dispositions. The filing lists 03/20/2026 for an intended sale of 1,596 shares via exercise of stock options for cash. The excerpt also lists past dispositions over the prior three months totaling specific tranches on 03/04/2026, 03/05/2026, 03/06/2026, 03/09/2026, 03/18/2026, and 03/19/2026 by Claire Mazumdar with per‑trade share counts and dollar values provided.
BCAX filing reports a proposed sale of 6,905 shares of Common Stock on 03/19/2026 following an exercise of stock options for cash. The notice lists multiple prior dispositions by Claire Mazumdar in the past three months, including 3/9/2026: 36,766 shares and 3/18/2026: 6,499 shares.
BCAX affiliate files Form 144 to sell 6,499 shares. The filing states 6,499 Common shares are to be sold on 03/18/2026 following an exercise of stock options with cash proceeds to the issuer. The filing also lists recent dispositions by Claire Mazumdar: 2,631 shares on 03/04/2026, 1,786 shares on 03/05/2026, 3,817 shares on 03/06/2026, and 36,766 shares on 03/09/2026.